Drugs / V930
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00647114 | Aug 2007 → Sep 2008 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00250419 | Sep 2005 → Sep 2008 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V930 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00250419 ↗ |
| Modality | Vaccine | “Patients were vaccinated with V930 alone, a DNA vaccine containing equal amounts of plasmids expressing the extracellular and trans-membrane domains of human HER2, and a...” PMID 23497415 ↗ Mar 2013 |
| Route | Intramuscular | “experimental vaccine given as intramuscular injections followed by electrostimulation” NCT00250419 ↗ |